A Cell-permeable Stat3 SH2 Domain Mimetic Inhibits Stat3 Activation and Induces Antitumor Cell Effects in Vitro
Open Access
- 1 November 2010
- journal article
- Published by Elsevier BV in Online Journal of Public Health Informatics
- Vol. 285 (46), 35855-35865
- https://doi.org/10.1074/jbc.m110.154088
Abstract
No abstract availableThis publication has 41 references indexed in Scilit:
- A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processesBiochemical Pharmacology, 2010
- Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 InhibitorsACS Medicinal Chemistry Letters, 2010
- Enhanced Sensitivity of Pancreatic Cancer Cells to Concurrent Inhibition of Aberrant Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor or SrcThe Journal of pharmacology and experimental therapeutics, 2010
- Targeting Protein–Protein Interactions: Suppression of Stat3 Dimerization with Rationally Designed Small‐Molecule, Nonpeptidic SH2 Domain BindersChemBioChem, 2008
- Molecular Approaches towards the Inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) ProteinChemMedChem, 2008
- STAT3 as a target for inducing apoptosis in solid and hematological tumorsCell Research, 2008
- Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activityProceedings of the National Academy of Sciences of the United States of America, 2007
- Validating Stat3 in cancer therapyNature Medicine, 2005
- UCSF Chimera?A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004